Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model.

[1]  G. Altavilla,et al.  From the bench to the bed: individualizing treatment in non-small-cell lung cancer , 2006, Clinical and Translational Oncology.

[2]  G. Silvestri,et al.  Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. , 2005, Chest.

[3]  Hiroshi Sato,et al.  Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.

[4]  S. Dedhar,et al.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK , 2005, Nature Reviews Cancer.

[5]  W. Roesler,et al.  Effect of overexpression and nuclear translocation of constitutively active PKB‐α on cellular survival and proliferation in HepG2 cells , 2004, Journal of cellular biochemistry.

[6]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[7]  S. Hövelmann,et al.  Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells , 2004, British Journal of Cancer.

[8]  M. Noguchi,et al.  MMP‐2 activation and stepwise progression of pulmonary adenocarcinoma: Analysis of MMP‐2 and MMP‐9 with gelatin zymography , 2004, Pathology international.

[9]  Arusha Oloumi,et al.  Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. , 2004, Biochimica et biophysica acta.

[10]  G. Rice,et al.  Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase , 2004, Clinical Cancer Research.

[11]  P. Bonomi,et al.  Novel treatments in non-small cell lung cancer. , 2004, Hematology/oncology clinics of North America.

[12]  S. Dedhar,et al.  The role of integrin-linked kinase (ILK) in cancer progression , 2003, Cancer and Metastasis Reviews.

[13]  M. Johnston,et al.  Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat , 1999, Clinical & Experimental Metastasis.

[14]  R. Kerbel,et al.  On a possible epigenetic mechanism(s) of tumor cell heterogeneity , 2004, Cancer and Metastasis Reviews.

[15]  M. Gleave,et al.  Regulation of tumor angiogenesis by integrin-linked kinase (ILK). , 2004, Cancer Cell.

[16]  M. Tsao,et al.  Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. , 2003, Lung cancer.

[17]  D. Birle,et al.  Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Riley,et al.  Integrin‐linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid , 2003, The Journal of pathology.

[20]  D. Huntsman,et al.  Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  S. Dedhar,et al.  Characterisation of integrin-linked kinase signalling in sporadic human colon cancer , 2003, British Journal of Cancer.

[22]  S. Dedhar,et al.  αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells , 2003, Oncogene.

[23]  Won Sang Park,et al.  Non‐small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  G. Giaccone,et al.  Novel approaches to the treatment of non-small cell lung cancer. , 2002, Critical reviews in oncology/hematology.

[25]  S. Dedhar,et al.  Integrin-linked kinase (ILK) and its interactors , 2001, The Journal of cell biology.

[26]  R. Cardiff,et al.  Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice , 2001, Oncogene.

[27]  J. Deddens,et al.  Integrin-linked kinase expression increases with prostate tumor grade. , 2001, Clinical Cancer Research.

[28]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[29]  S. Dedhar,et al.  Inhibition of integrin linked kinase (ILK) suppresses β-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC−/− human colon carcinoma cells , 2001, Oncogene.

[30]  S. Dedhar,et al.  The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9) , 2000, Oncogene.

[31]  S. Dedhar,et al.  Integrin-linked kinase (ILK): a "hot" therapeutic target. , 2000, Biochemical pharmacology.

[32]  D. Noonan,et al.  The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp‐9) activity , 2000 .

[33]  D. Ruiter,et al.  Expression of integrin αvβ3 correlates with activation of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) and matrix metalloproteinase‐2 (MMP‐2) in human melanoma cells in vitro and in vivo , 2000 .

[34]  S. Dedhar,et al.  Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Khokha,et al.  Differential expression of matrix metalloproteinases and their inhibitors in non‐small cell lung cancer , 2000, The Journal of pathology.

[36]  D. Fishman,et al.  Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. , 1999, Cancer research.

[37]  S. Dedhar,et al.  Integrin-linked Protein Kinase Regulates Fibronectin Matrix Assembly, E-cadherin Expression, and Tumorigenicity* , 1998, The Journal of Biological Chemistry.

[38]  S. Dedhar,et al.  Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase , 1996, Nature.